Aim
A parent-metabolite population pharmacokinetic (popPK) model of
iberdomide was developed and the influence of demographic and
disease-related covariates on popPK parameters was assessed based on
data from three clinical studies of iberdomide (dose range, 0.1 to 6 mg)
in healthy subjects (N=81) and subjects with relapsed and refractory
multiple myeloma (N=245).